Recent news on Peg-Intron

Approvals: Herceptin, Reyataz, and Peg-Intron  -  May 21, 2007
Medscape (subscription)On April 5, the Chinese State Food and Drug Administration approved a new indication for peginterferon alfa-2b injection (Peg-Intron, Schering-Plough

Data Suggest that PEGASYS® May be an Option in Hepatitis C ...  -  May 21, 2007
WebWire (press release),Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron® (peginterferon alfa-2b) and

Data Suggest that Pegasys May be an Option in Hepatitis C Patients ...  -  May 21, 2007
PharmaLive.com (press release),Overall, 88 percent of the total study population (100 percent of Peg-Intron non-tolerators and 81 percent of Peg-Intron non-responders) were able to

HIV and Hepatitis Therapies Continue to Drive Revenues in ...  -  May 23, 2007
PR Web (press release),...the launch of Pegasys, which it has bundled with its own ribavarin (Copegsys), while Schering-Plough markets its PEG Intron with its own ribavarin.

Enzon Reports First Quarter 2007 Results  -  May 2, 2007
PharmaLive.com (press release),US The majority of royalties is comprised of royalty revenue the Company receives on sales of PEG-INTRON, which remained relatively stable this quarter.

Zacks Bull and Bear of the Day Highlights: Bayer AG, Enzon ...  -  May 10, 2007
Business Wire (press release),Further, another major source of revenue, Royalty, declined by 5% in the first quarter of 2007 due to anticipated decline in PEG-INTRON sales in Japan

Vertex Vibrates Hepatitis Drug Sector  -  Apr 23, 2007
TheStreet.com...(Both Pegasys and Peg-Intron required weekly injections.) Follow-up data from a phase II study presented at the meeting showed that albufereon is just as

Vertex's Billion Dollar Drug?  -  Apr 18, 2007
Motley FoolComparing the Prove-1 study results to pivotal studies that helped lead to the approval of Pegasys and Peg-Intron shows the promise that telaprevir therapy

Medical Edge: Benefits of hepatitis C drugs outweigh side effects  -  Apr 14, 2007
Bryan College Station Eagle,Interferon (brand name: Peg-Intron or Pegasys) is a protein that stimulates the immune system to attack invaders such as hepatitis C virus.

Enzon's PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 18, 2007
PipelineReview.com (press release),...two of which Enzon markets, Adagen(R) and Oncaspar(R), and three for which Enzon receives royalties, PEG-INTRON(R), Pegasys(R), and Macugen(R).

Enzon’s PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 17, 2007
Business Wire (press release),...two of which Enzon markets, Adagen ® and Oncaspar ® , and three for which Enzon receives royalties, PEG-INTRON ® , Pegasys ® , and Macugen ® .

News For Your Web Site  -  Apr 18, 2007
dBusinessNews Newark (press release),...two of which Enzon markets, Adagen® and Oncaspar®, and three for which Enzon receives royalties, PEG-INTRON®, Pegasys®, and Macugen®.

ViroPharma Announces Presentation of Additional HCV-796 Data at ...  -  Apr 14, 2007
PipelineReview.com (press release),Subsequent cohorts were comprised of subjects who received peg-IFN (PEG-Intron; 1.5 ug/kg/dose) on days -1 and 7 in combination with either placebo or

New Clinical Study Results Indicate Higher Early Virologic ...  -  Apr 13, 2007
Drug Newswire (press release),...celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen,

Singapore growing biopharma strength  -  Apr 2, 2007
DrugResearcher.com,The Singaporean sites manufacture Schering's hepatitis C treatment Peg-Intron (peginterferon alpha-2b) and Remicade (infliximab) for Crohn's disease and

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
PipelineReview.com (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and Macugen(R), marketed by OSI

Metabolic Research, Inc. Appoints Dr. Robert Shorr as Chairman of ...  -  Mar 29, 2007
Genetic Engineering News (press release),Previously, he has served as Vice President Science and Technology at Enzon Inc., where he worked with Schering Plough to develop PEG INTRON A. Dr Shorr was

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
Business Wire (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and Macugen®, marketed by OSI Pharmaceuticals

Medical Edge -- Hepatitis C treatment an ordeal worth enduring  -  Mar 12, 2007
Post-Bulletin,Interferon (brand name: Peg-Intron or Pegasys) is a protein that stimulates the immune system to attack invaders such as HCV. Although ribavirin doesn't

New Hampshire : Pharmaceutical Manufacturer Schering-Plough Pays ...  -  Feb 27, 2007
All American Patriots (press release),...and that it paid improper inducements to promote the prescribing of Intron-A, a bladder cancer treatment, and Peg-Intron and Rebetron, which are used to

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
Business Wire (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON ® , marketed by Schering-Plough Corporation, and Macugen ® , marketed by OSI

Biolex Therapeutics Announces Initiation of Locteron(TM) Phase 2 ...  -  Jan 30, 2007
PR Newswire (press release),Investors: Dale Sander, Chief Financial Officer, 858-663-6993, dsander@biolex.com PEG-INTRON(R) is a registered trademark of Schering-Plough Corporation.

Biolex Therapeutics Announces Initiation Of Locteron(TM) Phase 2 ...  -  Jan 31, 2007
Medical News Today (press release),...less severe and of shorter duration than in the subjects receiving PEG-INTRON(R), the currently marketed interferon that served as the control.

Enzon Reports 2006 Financial Results and Accomplishments  -  Feb 13, 2007
Genetic Engineering News (press release),In 2006, PEG-INTRON sales continued to grow as a result of the launch in Japan. However, as anticipated, Schering-Plough reported a decline in PEG-INTRON

Schering-Plough Q4 profit up  -  Jan 29, 2007
Pharmaceutical Business ReviewSchering-Plough's leading prescription products like Remicade were up 32%, Nasonex up 28%, Peg-Intron up 11%, Temodar up 20%, and Clarinex/Aerius was up 12%

Louisiana Settles with Schering-Plough  -  Feb 10, 2007
All American Patriots (press release),...and the company’s payment of illegal remuneration to physicians to induce them to prescribe hepatitis drugs PEG-Intron and Rebetron, and bladder cancer

Bruning Announces $1.8 Million Medicaid Fraud Settlement  -  Feb 9, 2007
Southwest Nebraska News,Finally, Schering allegedly paid kickbacks to doctors to induce them to prescribe hepatitis drugs PEG-Intron and Rebetron and bladder cancer medication

Schering-Plough's turnaround is moving on apace  -  Jan 30, 2007
Pharma Times (subscription),Brain cancer treatment Temodar enjoyed a sales rise of 18% to $189 million, but Peg-Intron (peginterferon alfa) fell 3% to $208 million, hampered by a

Schering-Plough Reports Financial Results for 2006 Fourth Quarter ...  -  Jan 29, 2007
PR Newswire (press release),Sales of the company's PEG-INTRON hepatitis C product declined 3 percent to $208 million in the 2006 fourth quarter primarily due to the decline in sales in

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 4, 2007
dBusinessNews Newark (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and MACUGEN®, marketed by OSI Pharmaceuticals

Earnings at Schering-Plough Climbed 75% in 4th Quarter  -  Jan 29, 2007
New York Times,The company said sales of its Peg-Intron hepatitis C product declined 3 percent, to $208 million, mainly on lower sales in Japan, as the number of new

Schering-Plough profit rises on cholesterol drugs  -  Jan 29, 2007
San Diego Union Tribune,But sales of Peg-Intron, an interferon drug used to treat hepatitis C, slipped 3 percent to $208 million, hurt by declining demand in Japan.

Schering-Plough posts 75 percent rise in 4th-quarter profit  -  Jan 29, 2007
San Diego Union Tribune,The company said sales of its Peg-Intron hepatitis C product declined 3 percent to $208 million primarily due to lower sales in Japan, as the number of new

Schering-Plough 4Q Profit Up 75 Percent  -  Jan 29, 2007
Forbes,The company said sales of its Peg-Intron hepatitis C product declined 3 percent to $208 million primarily due to lower sales in Japan, as a result of the

Schering-Plough profit boosted by Remicade  -  Jan 29, 2007
MarketWatchHowever, sales of the company's Peg-Intron hepatitis C product declined 3% to $208 million in the fourth quarter, primarily due a decline in sales in Japan.

Schering boosted by anti-cholestorol joint venture  -  Jan 29, 2007
MSNBCBut sales of Peg-Intron, the company's anti-hepatitis C drug, declined 3 per cent to $208m, as fewer patients started using the drug in Japan.

Schering-Plough Fourth Quarter Earnings Call  -  Jan 30, 2007
123Jump.com,Sales of the company''s PEG-INTRON hepatitis C product declined 3% to $208 million in the 2006 fourth quarter. This was primarily due to the decline in

Nasonex Unclogs Schering-Plough Profit  -  Jan 29, 2007
Smartmoney.comSales of the company's Peg-Intron hepatitis C product declined 3% to $208 million in the fourth quarter primarily due to the decline in sales in Japan,

Schering-Plough Q4 Profit Increases On Higher Prescription Drug ...  -  Jan 29, 2007
Trading Markets,Sales of the company's Peg-Intron hepatitis C product declined 3% to $208 million from $214 million in the year-ago quarter primarily due to the decline in

Academics create a cheaper Hep C drug  -  Jan 2, 2007
Ars Technica,The drug in question is PEG-intron, a protein based drug that is based on a family of cytokines. Unlike other interferon-based therapies, PEG-Intron

OraSure sees trials of oral hepatitis C test ending this year  -  Jan 11, 2007
International Herald Tribune,...which makes the current standard treatment for hepatitis C, pegylated interferon, called Peg-Intron, which is often used with ribavirin.

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
American Digital Networks (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI

Zacks Bull and Bear of the Day Highlights: Hittite Microwave ...  -  Jan 8, 2007
American Digital Networks (press release),Although Royalty on PEG-Intron in the third quarter grew by 21% on a year over year basis, sales in Japan is anticipated to decline due to competition.

Challenges and Opportunities in the Global Protein Therapeutics Market  -  Dec 18, 2006
Emediawire (press release),This was due to increased sales of both Pegasys as well as PEG-Intron. The sudden increase in PEG-Intron revenues was due to the recent approval of Rebetron

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional